MDA
Pgp3 seroprevalence and associations with active trachoma and ocular Chlamydia trachomatis infection in Malawi: cross-sectional surveys in six evaluation units
In this study, impact surveys in six evaluation units of Malawi were used as a platform to explore associations between the prevalence of TF, ocular C. trachomatis infection and anti-Pgp3 antibodies one year after the third annual round of MDA.
Impact of mass drug administration of azithromycin for trachoma elimination on prevalence and azithromycin resistance of genital Mycoplasma genitalium infection
This study aims to determine the effect of MDA for trachoma elimination on M. genitalium prevalence, strain type and azithromycin resistance.
Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal
To increase understanding of MDA impact, this study investigated the prevalence of active trachoma and ocular C. trachomatis prevalence, organism load, and circulating strains at baseline and one-year post-MDA in The Gambia and Senegal.
Antimicrobial Resistance Following Azithromycin Mass Drug Administration: Potential Surveillance Strategies to Assess Public Health Impact
Antibiotics for trachoma
This study assess the evidence supporting the antibiotic arm of the SAFE strategy by assessing the effects of antibiotics on both active trachoma (primary objective), Chlamydia trachomatis infection of the conjunctiva, antibiotic resistance, and adverse effects (secondary objectives).
Safe mass drug administration and trachoma elimination
Community Eye Health Journal Vol. 32 No. 106 2019
Graph of Zithromax doses shipped from 1999-2020
This graph shows the total doses on Zithromax shipped and projected for trachoma elimination programs for 1999-2020.
Zithromax® Management Guide 2019
This guide book explains how to successfully apply for, administer, and manage Zithromax® donations for trachoma elimination.
Ocular immune responses, Chlamydia trachomatis infection and clinical signs of trachoma before and after azithromycin mass drug administration in a treatment naïve trachoma-endemic Tanzanian community
Conjunctival inflammation is the major clinical risk factor for progressive scarring trachoma, therefore, the reduction in inflammation associated with azithromycin treatment may be beneficial in limiting the development of potentially blinding disease sequelae.
